Implications of age-dependent immune responses to enterovirus 71 infection for disease pathogenesis and vaccine design

Journal of the Pediatric Infectious Diseases Society

Volumn 2, Issue 2, 2013, Pages 163-170

  Gantt, Soren ^a,b   Yao, Lena ^c   Kollmann, Tobias R ^d   Casper, Corey ^c   Zhang, Jing ^e   Self, Steven G ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; DNA VACCINE; ENTEROVIRUS 71 VACCINE; IMMUNOGLOBULIN; INACTIVATED VIRUS VACCINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; PATTERN RECOGNITION RECEPTOR; PROTEIN VP1; RECOMBINANT PROTEIN; RETINOIC ACID INDUCIBLE PROTEIN I; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS VACCINE;

AGE; ANTIBODY RESPONSE; ASIA; BURNING MOUTH SYNDROME; CELLULAR IMMUNITY; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENCEPHALITIS; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; EPIDEMIC; HERPANGINA; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INNATE IMMUNITY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS CELL INTERACTION; VIRUS LIKE AGENT;

EID: 84894787635     PISSN: 20487193     EISSN: 20487207     Source Type: Journal    
DOI: 10.1093/jpids/pit017     Document Type: Review

References (94)

1. Van der Sanden S, Koopmans M, Uslu G, van der Avoort H. Epidemiology of enterovirus 71 in the Netherlands, 1963 to 2008. J Clin Microbiol 2009; 47:2826-33.
2. Tee KK, Lam TT, Chan YF, et al. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J Virol 2010; 84:3339-50.
3. Solomon T, Lewthwaite P, Perera D, et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010; 10:778-90.
4. Organization WH. A guide to clinical management and public health response for hand, foot and mouth disease (HFMD). Geneva:WHO Publications; 2011.
5. Ooi MH, Wong SC, Lewthwaite P, et al. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol 2010; 9:1097-105.
6. Wang Y, Feng Z, Yang Y, et al. Hand, foot, and mouth disease in China: patterns of spread and transmissibility. Epidemiology 2011; 22:781-92.
7. Ooi MH, Wong SC, Mohan A, et al. Identification and validation of clinical predictors for the risk of neurological involvement in children with hand, foot, and mouth disease in Sarawak. BMC Infect Dis 2009; 9:3.
8. Wang SM, Liu CC. Enterovirus 71: epidemiology, pathogenesis and management. Expert Rev Anti Infect Ther 2009; 7:735-42.
9. Chang LY, Hsia SH, Wu CT, et al. Outcome of enterovirus 71 infections with or without stage-based management: 1998 to 2002. Pediatr Infect Dis J 2004; 23:327-32.
10. Xu J, Qian Y, Wang S, et al. EV71: An emerging infectious disease vaccine target in the Far East? Vaccine 2010; 28: 3516-21.
11. Zhu FC, Wang JZ, Li XL, et al. Reactogenicity and immunogenicity of an enterovirus 71 vaccine in Chinese healthy children and infants. Pediatr Infect Dis J 2012; 24.
12. Li YP, Liang ZL, Gao Q, et al. Safety and immunogenicity of a novel human enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine 2012; 30:3295-303.
13. Han JF, Cao RY, Deng YQ, et al. Antibody dependent enhancement infection of enterovirus 71 in vitro and in vivo. Virol J 2011; 8:106.
14. Wang SM, Chen IC, Su LY, et al. Enterovirus 71 infection of monocytes with antibody-dependent enhancement. Clin Vaccine Immunol 2010; 17:1517-23.
15. Lin TY, Hsia SH, Huang YC, et al. Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. Clin Infect Dis 2007; 36:269-74.
16. Wang SM, Lei HY, Su LY, et al. Cerebrospinal fluid cytokines in enterovirus 71 brain stem encephalitis and echovirus meningitis infections of varying severity. Clin Microbiol Infect 2007; 13: 677-82.
17. Wang SM, Lei HY, Huang KJ, et al. Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis 2007; 188:564-70.
18. Liang Y, Zhou X, Yang E, et al. Analysis of the Th1/Th2 reaction in the immune response induced by EV71 inactivated vaccine in neonatal rhesus monkeys. J Clin Immunol 2012; 15.
19. Lee MS, Tseng FC, Wang JR, et al. Challenges to licensure of enterovirus 71 vaccines. PLoS Negl Trop Dis 2012; 6:e1737.
20. Yang F, Ren L, Xiong Z, et al. Enterovirus 71 outbreak in the People's Republic of China in 2008. J Clin Microbiol 2009; 47: 2351-2.
21. World Health Organization. Hand, Foot and Mouth Disease (HFMD) Situation Updates. Available at: http://www.wpro.who. int/emerging_diseases/HFMD/en/index.html. Accessed 7 September 2012.
22. Seiff A. Cambodia unravels cause of mystery illness. Lancet 2012; 380:206.
23. Pallansch M, Roos R. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. Fields Virology 2007; 1:839-94.
24. Lu CY, Lee CY, Kao CL, et al. Incidence and case-fatality rates resulting from the 1998 enterovirus 71 outbreak in Taiwan. J Med Virol 2002; 67:217-23.
25. Chang LY, King CC, Hsu KH, et al. Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics 2002; 109:e88.
26. Wang SM, Ho TS, Lin HC, et al. Reemerging of enterovirus 71 in Taiwan: the age impact on disease severity. Eur J Clin Microbiol Infect Dis 2012; 31:1219-24.
27. Ong KC, Badmanathan M, Devi S, et al. Pathologic characterization of a murine model of human enterovirus 71 encephalomyelitis. J Neuropathol Exp Neurol 2008; 67:532-42.
28. Yamayoshi S, Yamashita Y, Li J, et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 2009; 15: 798-801.
29. Nishimura Y, Shimojima M, Tano Y, et al. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med 2009; 15:794-7.
30. Huang HI, Weng KF, Shih SR. Viral and host factors that contribute to pathogenicity of enterovirus 71. Future Microbiol 2012; 7:467-79.
31. Nathanson N. The pathogenesis of poliomyelitis: what we don't know. Adv Virus Res 2008; 71:1-50.
32. Shen WC, Chiu HH, Chow KC, Tsai CH. MR imaging findings of enteroviral encephaloymelitis: an outbreak in Taiwan. AJNR Am J Neuroradiol 1999; 20:1889-95.
33. Wong KT, Munisamy B, Ong KC, et al. The distribution of inflammation and virus in human enterovirus 71 encephalomyelitis suggests possible viral spread by neural pathways. J Neuropathol Exp Neurol 2008; 67:162-9.
34. Pallansch M, Roos R. Enteroviruses: Polioviruses, Coxsackieviruses, Echoviruses, and Newer Enteroviruses. In: Knipe D, Howley P, eds. Fields Virology. 5th Ed. Philadelphia, PA: Lippincott Williams&Wilkins; 2007.
35. Chang LY, Lin TY, Hsu KH, et al. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet 1999; 354:1682-6.
36. Perez-Velez CM, Anderson MS, Robinson CC, et al. Outbreak of neurologic enterovirus type 71 disease: a diagnostic challenge. Clin Infect Dis 2007; 45:950-7.
37. Shahar A, Schupper H, Lustig S, et al. Neuronal cell cultures as a model for assessing neurotoxicity induced by encephalitic viruses. Neurotoxicology 1992; 13:171-7.
38. Wen YY, Chang TY, Chen ST, et al. Comparative study of enterovirus 71 infection of human cell lines. J Med Virol 2007; 70:109-18.
39. Cordey S, Petty TJ, Schibler M, et al. Identification of site-specific adaptations conferring increased neural cell tropism during human enterovirus 71 infection. PLoS Pathog 2012; 8: e1002826.
40. Huang SW, Wang YF, Yu CK, et al. Mutations in VP2 and VP1 capsid proteins increase infectivity and mouse lethality of enterovirus 71 by virus binding and RNA accumulation enhancement. Virology 2012; 422:132-43.
41. Huang SW, Kiang D, Smith DJ, Wang JR. Evolution of re-emergent virus and its impact on enterovirus 71 epidemics. Exp Biol Med (Maywood) 2011; 236:899-908.
42. Wang SM, Liu CC, TsengHW, et al. Clinical spectrum of enterovirus 71 infection in children in southern Taiwan, with an emphasis on neurological complications. Clin Infect Dis 1999; 29: 184-90.
43. Zhang Y, Cui W, Liu L, et al. Pathogenesis study of enterovirus 71 infection in rhesus monkeys. Lab Invest 2011; 91:1337-50.
44. Lin YW, Chang KC, Kao CM, et al. Lymphocyte and antibody responses reduce enterovirus 71 lethality in mice by decreasing tissue viral loads. J Virol 2009; 83:6477-83.
45. Nagata N, Iwasaki T, Ami Y, et al. Differential localization of neurons susceptible to enterovirus 71 and poliovirus type 1 in the central nervous system of cynomolgus monkeys after intravenous inoculation. J Gen Virol 2004; 85(Pt 10):2981-9.
46. Chang LY, Huang YC, Lin TY. Fulminant neurogenic pulmonary oedema with hand, foot, and mouth disease. Lancet 1998; 352:367-8.
47. Fu YC, Chi CS, Chiu YT, et al. Cardiac complications of enterovirus rhombencephalitis. Arch Dis Child 2004; 89:368-73.
48. Lum LC,Wong KT, Lam SK, et al. Fatal enterovirus 71 encephalomyelitis. J Pediatr 1998; 133:795-8.
49. Zhang YC, Jiang SW, Gu WZ, et al. Clinicopathologic features and molecular analysis of enterovirus 71 infection: report of an autopsy case from the epidemic of hand, foot and mouth disease in China. Pathol Int 2012; 62:565-70.
50. Griffiths MJ, Ooi MH,Wong SC, et al. In enterovirus 71 encephalitis with cardio-respiratory compromise, elevated interleukin 1beta, interleukin 1 receptor antagonist, and granulocyte colony-stimulating factor levels are markers of poor prognosis. J Infect Dis 2012; 206:881-92.
51. Wang SM, Lei HY, Liu CC. Cytokine immunopathogenesis of enterovirus 71 brain stem encephalitis. Clin Dev Immunol 2012; 2012:876241.
52. Mascia L. Acute lung injury in patients with severe brain injury: a double hit model. Neurocrit Care 2009; 11:417-26.
53. Fu YC, Chi CS, Lin NN, et al. Comparison of heart failure in children with enterovirus 71 rhombencephalitis and cats with norepinephrine cardiotoxicity. Pediatr Cardiol 2006; 27:577-84.
54. Weng KF, Chen LL, Huang PN, Shih SR. Neural pathogenesis of enterovirus 71 infection. Microbes Infect 2010; 12:505-10.
55. Chang LY, Hsiung CA, Lu CY, et al. Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71. Pediatr Res 2006; 60:466-71.
56. Yang KD, Yang MY, Li CC, et al. Altered cellular but not humoral reactions in children with complicated enterovirus 71 infections in Taiwan. J Infect Dis 2001; 183:850-6.
57. Wang SM, Lei HY, Yu CK, et al. Acute chemokine response in the blood and cerebrospinal fluid of children with enterovirus 71-associated brainstem encephalitis. J Infect Dis 2008; 198:1002-6.
58. Khong WX, Foo DG, Trasti SL, et al. Sustained high levels of interleukin-6 contribute to the pathogenesis of enterovirus 71 in a neonate mouse model. J Virol 2011; 85:3067-76.
59. Chang LY, Huang LM, Gau SS, et al. Neurodevelopment and cognition in children after enterovirus 71 infection. N Engl J Med 2007; 356:1226-34.
60. Donald PR, Marais BJ, Barry CE 3rd. Age and the epidemiology and pathogenesis of tuberculosis. Lancet 2010; 375:1852-4.
61. Wilson CB, Kollmann TR. Induction of antigen-specific immunity in human neonates and infants. Nestle Nutr Workshop Ser Pediatr Program 2008; 61:183-95.
62. Negishi H, Osawa T, Ogami K, et al. A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity. Proc Natl Acad Sci U S A 2008; 105: 20446-51.
63. Richer MJ, Lavallee DJ, Shanina I, Horwitz MS. Toll-like receptor 3 signaling on macrophages is required for survival following coxsackievirus B4 infection. PLoS One 2009; 4:e4127.
64. Wang Q, Nagarkar DR, Bowman ER, et al. Role of doublestranded RNA pattern recognition receptors in rhinovirus-induced airway epithelial cell responses. J Immunol 2009; 183:6989-97.
65. Lei X, Liu X, Ma Y, et al. The 3C protein of enterovirus 71 inhibits retinoid acid-inducible gene I-mediated interferon regulatory factor 3 activation and type I interferon responses. J Virol 2010; 84:8051-61.
66. Papon L, Oteiza A, Imaizumi T, et al. The viral RNA recognition sensor RIG-I is degraded during encephalomyocarditis virus (EMCV) infection. Virology 2009; 393:311-8.
67. Lei X, Xiao X, Xue Q, et al. Cleavage of interferon regulatory factor 7 by enterovirus 71 3C suppresses cellular responses. J Virol 2013; 87:1690-8.
68. Gitlin L, Barchet W, Gilfillan S, et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci U S A 2006; 103:8459-64.
69. Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006; 441:101-5.
70. Zheng Z, Li H, Zhang Z, et al. Enterovirus 71 2C protein inhibits TNF-alpha-mediated activation of NF-kappaB by suppressing IkappaB kinase beta phosphorylation. J Immunol 2011; 187: 2202-12.
71. Ito M, Yanagi Y, Ichinohe T. Encephalomyocarditis virus viroporin 2B activates NLRP3 inflammasome. PLoS Pathog 2012; 8: e1002857.
72. Wang SM, Lei HY, Huang MC, et al. Modulation of cytokine production by intravenous immunoglobulin in patients with enterovirus 71-associated brainstem encephalitis. J Clin Virol 2006; 37:47-52.
73. Burl S, Townend J, Njie-Jobe J, et al. Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infants. PLoS One 2011; 6:e18185.
74. Kollmann TR, Crabtree J, Rein-Weston A, et al. Neonatal innate TLR-mediated responses are distinct from those of adults. J Immunol 2009; 183:7150-60.
75. Kollmann TR, Levy O, Montgomery RR, Goriely S. Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly. Immunity 2012; 37:771-83.
76. Levy O, Goriely S, Kollmann TR. Immune response to vaccine adjuvants during the first year of life. Vaccine 2012; doi:10.1016/j.vaccine.2012.10.016. [Epub ahead of print].
77. De Wit D, Tonon S, Olislagers V, et al. Impaired responses to Toll-like receptor 4 and Toll-like receptor 3 ligands in human cord blood. J Autoimmun 2007; 21:277-81.
78. Lisciandro JG, Prescott SL, Nadal-Sims MG, et al. Ontogeny of Toll-like and NOD-like receptor-mediated innate immune responses in Papua New Guinean infants. PLoS One 2012; 7:e36793.
79. Philbin VJ, Dowling DJ, Gallington LC, et al. Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways. J Allergy Clin Immunol 2012; 130:p195-204.e9.
80. Chen J, Tong J, Liu H, et al. Increased frequency of Th17 cells in the peripheral blood of children infected with enterovirus 71. J Med Virol 2012; 84:763-7.
81. Pugin J, Ricou B, Steinberg KP, et al. Proinflammatory activity in bronchoalveolar lavage fluids from patients with ARDS, a prominent role for interleukin-1. Am J Respir Crit Care Med 1996; 153(6 Pt 1):1850-6.
82. Hofmann U, Heuer S, Meder K, et al. The proinflammatory cytokines TNF-alpha and IL-1 beta impair economy of contraction in human myocardium. Cytokine 2007; 39:157-62.
83. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011; 117:3720-32.
84. Huang SW, Lee YP, Hung YT, et al. Exogenous interleukin-6, interleukin-13, and interferon-gamma provoke pulmonary abnormality with mild edema in enterovirus 71-infected mice. Respir Res 2011; 12:147.
85. Chang GH, Luo YJ, Wu XY, et al. Monoclonal antibody induced with inactived EV71-Hn2 virus protects mice against lethal EV71-Hn2 virus infection. Virol J 2010; 7:106.
86. Luo ST, Chiang PS, Chao AS, et al. Enterovirus 71 maternal antibodies in infants, Taiwan. Emerg Infect Dis 2009; 15:581-4.
87. Mizuta K, Aoki Y, Suto A, et al. Cross-antigenicity among EV71 strains from different genogroups isolated in Yamagata, Japan, between 1990 and 2007. Vaccine 2009; 27:3153-8.
88. Liu CC, Chou AH, Lien SP, et al. Identification and characterization of a cross-neutralization epitope of enterovirus 71. Vaccine 2011; 29:4362-72.
89. Ooi MH, Wong SC, Podin Y, et al. Human enterovirus 71 disease in Sarawak, Malaysia: a prospective clinical, virological, and molecular epidemiological study. Clin Infect Dis 2007; 44: 646-56.
90. Quartier P, Foray S, Casanova JL, et al. Enteroviral meningoencephalitis in X-linked agammaglobulinemia: intensive immunoglobulin therapy and sequential viral detection in cerebrospinal fluid by polymerase chain reaction. Pediatr Infect Dis J 2000; 19: 1106-8.
91. Abzug MJ, Keyserling HL, Lee ML, et al. Neonatal enterovirus infection: virology, serology, and effects of intravenous immune globulin. Clin Infect Dis 1995; 20:1201-6.
92. Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol 2011; 127:315-23; quiz 24-5.
93. Huisman W, Martina BE, Rimmelzwaan GF, et al. Vaccineinduced enhancement of viral infections. Vaccine 2009; 27: 505-12.
94. Castilow EM, Olson MR, Varga SM. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol Res 2007; 39:225-39.